drugset / Trial / NCT02146924
Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia
Phase 1
Active not recruiting
71 enrolled
City of Hope Medical Center
National Cancer Institute (NCI) · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This phase I trial studies the side effects and best dose of cellular immunotherapy in treating patients with high-risk acute lymphoblastic leukemia. Placing a modified gene into white blood cells may help the body build an immune response to kill cancer cells.
Timeline
- Start
- 2014-10-16
- Primary completion
- 2026-07-15
- Completion
- 2026-07-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes | Cell therapy | — | Intravenous |
| Comparator | CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes | Cell therapy | — | Intravenous |